Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report
Portfolio Pulse from Lekha Gupta
Blackstone Inc. (NYSE:BX) is nearing a $2.2 billion deal to sell Japanese supplement maker Alinamin Pharmaceutical to MBK Partners. Blackstone acquired Alinamin from Takeda Pharmaceutical Company (NYSE:TAK) in 2020. The deal is expected to be finalized soon. Blackstone's stock has gained over 29% in the last 12 months. Investors can gain exposure to Blackstone via Invesco Global Listed Private Equity ETF (NYSE:PSP) and EA Series Trust WHITEWOLF Publicly Listed Private Equity ETF (BATS:LBO).
July 02, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Blackstone Inc. is close to finalizing a $2.2 billion deal to sell Alinamin Pharmaceutical to MBK Partners. This follows Blackstone's acquisition of Alinamin from Takeda in 2020. The deal is expected to be finalized soon.
The sale of Alinamin Pharmaceutical for $2.2 billion is a significant transaction for Blackstone, likely to positively impact its stock price in the short term. The deal's finalization will provide liquidity and potentially enhance investor sentiment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Investors can gain exposure to Blackstone through the EA Series Trust WHITEWOLF Publicly Listed Private Equity ETF, which includes Blackstone in its portfolio. The ETF may see positive movement if Blackstone's stock rises due to the Alinamin deal.
The EA Series Trust WHITEWOLF Publicly Listed Private Equity ETF includes Blackstone in its portfolio. Positive news for Blackstone, such as the Alinamin deal, could lead to a short-term increase in the ETF's value.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Investors can gain exposure to Blackstone through the Invesco Global Listed Private Equity ETF, which includes Blackstone in its portfolio. The ETF may see positive movement if Blackstone's stock rises due to the Alinamin deal.
The Invesco Global Listed Private Equity ETF includes Blackstone in its portfolio. Positive news for Blackstone, such as the Alinamin deal, could lead to a short-term increase in the ETF's value.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Takeda Pharmaceutical Company previously sold Alinamin Pharmaceutical to Blackstone in 2020. The current deal between Blackstone and MBK Partners does not directly impact Takeda.
While Takeda Pharmaceutical Company is mentioned as the previous owner of Alinamin, the current deal between Blackstone and MBK Partners does not directly affect Takeda's operations or stock price.
CONFIDENCE 80
IMPORTANCE 20
RELEVANCE 30